Bank Credit Model Research Of Biological Pharmaceutical Enterprises

Biomedical industry, Chinese medicine as an emerging economic power of the global financial crisis in2009, a downturn in world economic situation, far more than other industries, to become the core of the national government concerned about the competitive industry. However, compared with developed countries, China’s biomedical industry is still the early stages of development, biomedical companies generally encountered financial "bottleneck"; combined with biomedical research and development cycle is long, long time objective characteristics of clinical trials, biomedical companies management process, always subject to "financing"restriction. Domestic and international corporate finance issues of biological resources, including:government funds, equity market financing, debt financing, loans to financial institutions, private financing, etc.. In China, the reality, biomedical companies still rely on bank financing, led by the indirect financing.From the view of bank credit, biomedical companies on the one hand has a clear market demand for rigid; the other hand, the state policy on the large tilt and strong financial support, a high-quality commercial bank credit. In China, nearly most biomedical companies in the development period, the low level of R&D, market development is weak, and other common problems of small-scale funds, the bank credit in the biomedical business model has always been difficult to achieve a breakthrough. The constraints of risk prevention by banks, credit funds and time can be very limited. Mature modern biomedical enterprise, from personnel training-research-technology development-pilot hatch-the scale of production-marketing and logistics, is a long period, commercial banks need to change their ideas, innovative models, and biomedical enterprise collaboration, the occupation of credit market new profit growth point, really banking, business, society and people, many "win-win" situation of harmony is the focus of this paper to explore and study. This article rely on advanced foreign research results and practical experience, combined with the characteristics of China’s financial markets and affordability mixed, from biomedical companies, commercial banks, government-wide perspective of the biomedical business model of bank credit. State Biotech&Pharmaceutical Industrial Base (Shanghai) of empirical research and analysis,which include the introduction of government agencies, regional organizations, financial institutions and other third-party guarantee, to form a strategic tripartite cooperation model, summarize the existing pattern of bank credit features and shortcomings, to explore the effectiveness of industrial strategic cooperation model, and provide recommendations to solve real business development in the biomedical funding gap problem.